In the 96-week Phase 3 INFRONT-3 study in FTD due to GRN mutations, latozinemab failed to slow clinical progression on the CDR plus NACC FTLD-SB co-primary endpoint. The antibody achieved its biomarker co-primary by significantly increasing plasma progranulin, but secondary and exploratory measures, including fluid biomarkers and volumetric MRI, showed no treatment-related effects. Preliminary safety did not reveal major concerns.
The core action follows accordingly. Alector will discontinue the INFRONT-3 open-label extension and the separate continuation study. The company is cutting approximately 49% of its workforce and reorganizing around its partnered and platform programs. The R&D president will depart at year-end. Alector reports roughly $291 million in cash and equivalents as of September 30, 2025, guiding runway through 2027. Development continues with nivisnebart (AL101/GSK4527226) in PROGRESS-AD, a global 76-week Phase 2 study in early Alzheimer’s disease. Enrollment was completed in April 2025, an independent interim analysis is planned for the first half of 2026, and trial completion is expected in 2026. The company is advancing its Alector Brain Carrier blood–brain barrier platform, targeting an IND for AL137, an ABC-enabled anti-amyloid beta program in AD, in 2026, and for AL050, an ABC-enabled GCase enzyme replacement for Parkinson’s, in 2027, alongside an ABC-enabled tau siRNA effort in preclinical development.
Strategically, this is a pivot forced by a translational disconnect: robust target engagement on plasma progranulin did not translate into clinical or imaging benefit over two years. The U.S.-only amendment designating plasma PGRN as a co-primary underscores regulatory openness to biological rationale. Still, the outcome reinforces how little tolerance there is for surrogate endpoints that fail to predict function in neurodegeneration. The move consolidates capital behind a partnered AD antibody with a near-term data catalyst and behind a BBB transport platform that, if validated clinically, could enable multiple modalities. The workforce reduction is a defensive step to preserve runway while the company recalibrates around assets with broader indications and clearer partnering potential.
For sites, the immediate impact is operational wind-down of the FTD-GRN extension and continuation studies, patient offboarding, and data closure in a rare genetic population with limited trial alternatives. CROs and service vendors supporting INFRONT-3 will see rapid demobilization. At the same time, networks built to identify and follow GRN carriers may look to redeploy to prevention-oriented or multi-cohort neuro programs. Sponsors working in progranulin biology will absorb a cautionary signal: blood PGRN elevation alone may be insufficient, and designs may need to shift earlier in disease or incorporate downstream pathway readouts and sensitive functional measures. Regulators will have fresh evidence to calibrate the role of fluid biomarkers as co-primary or supportive endpoints. GSK’s co-development calculus now concentrates on the AD program’s interim analysis, which becomes the key near-term determinant of the collaboration’s trajectory.
Attention next turns to the full INFRONT-3 dataset at a medical meeting. Subgroup and time-to-decline analyses, exposure–response relationships, regional variability linked to the U.S.-specific co-primary, and any insights from pre-symptomatic or at-risk cohorts will determine whether progranulin augmentation has a future in prevention trials rather than symptomatic treatment. On the business side, watch for clarity on any formal discontinuation of latozinemab, retention of GRN clinical infrastructure by academic consortia, and partner interest around the ABC platform ahead of first-in-human timelines. Execution risk following a deep headcount reduction and leadership transition is nontrivial. If the AD Phase 2 signal underwhelms or BBB-enabled candidates slip, the company may need external capital or additional partnering to sustain the new plan.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
